

MICHAEL J. THIRMAN, M.D.

The University of Chicago
 Department of Medicine
 Section of Hematology/Oncology
 5841 South Maryland Avenue, MC 2115
 Chicago, IL 60637-1470
 Phone: (773) 702-4133
 Fax: (773) 702-9268

ACADEMIC APPOINTMENTS

1996-2003	Assistant Professor, University of Chicago, Section of Hematology/Oncology
1996-	Member, Committee on Cancer Biology
1996-	Member, University of Chicago Cancer Research Center
2003-	Associate Professor, University of Chicago, Section of Hematology/Oncology
2003-	Director of Leukemia Biology, University of Chicago, Section of Hematology/Oncology
2007-2014	Co-Program Leader, University of Chicago Cancer Research Center, Program 2 – Hematopoiesis and Hematologic Malignancies

ACADEMIC TRAINING

1979-1982	University of Michigan, College of Literature, Science, and the Arts
1982-1986	University of Michigan Medical School
1986-1989	Resident, University of Minnesota Hospitals, Department of Internal Medicine.
1989-1990	Fellow, Minneapolis VA Medical Center, Section of Clinical Pharmacology, Laboratory of Jordan L. Holtzman, M.D., Ph.D.
1990-1991	Clinical Fellow, University of Chicago, Section of Hematology/Oncology.
1991-1994	Fellow, University of Chicago, Section of Hematology/Oncology, Laboratory of Manuel O. Diaz, M.D. and Janet D. Rowley, M.D.
1994-1996	Research Associate, University of Chicago, Section of Hematology/Oncology, Laboratory of M. Celeste Simon, Ph.D.

LICENSING AND BOARD CERTIFICATION

Licensed in the State of Illinois

Current certification status: Internal Medicine

Initial Certifications: Internal Medicine 09/13/1989, Medical Oncology 11/03/1993

HONORS, PRIZES, AND AWARDS

1979	University of Michigan Regents Alumni Scholar
1993	American Society of Clinical Oncology Young Investigator Award
1993-1996	Howard Hughes Postdoctoral Research Fellowship for Physicians,
1994	Frank E. Trobaugh Young Investigator Award, Midwest Blood Club
1995	Cancer Research Foundation Associates Board Young Investigator Award
1995-2000	Burroughs Wellcome Fund Career Award in Biomedical Sciences
1997	AMA - Florence A. Carter Fellowship in Leukemia Research
1997	Leukemia Research Foundation New Investigator Award
1998-2000	American Society of Hematology Junior Faculty Award,
1997	Cancer Research Foundation Young Investigator Award
2002-2007	Scholar, Leukemia and Lymphoma Society
2005-2009	Chairman of Medical Advisory Board, Leukemia Research Foundation
2007	Stohlman Scholar, Leukemia and Lymphoma Society
2019-2020	Chicago Magazine Top Cancer Doctor
2021-2026	Chicago Magazine Top Doctor

SCHOLARSHIP

Peer-reviewed publications in the primary literature, exclusive of abstracts:

1. **Thirman, M.J.**, Goetting, M.G. Neurotoxicity of meperidine. *Ann Emerg Med.* 1985;14:1007-9.
2. **Thirman, M.J.**, Devine, S.M., O'Toole, K., Cizek, G., Jessurun, J., Hertz, M., Geller, R.B. Bronchiolitis obliterans organizing pneumonia as a complication of allogeneic bone marrow transplantation. *Bone Marrow Transplant*, 1992;10:307-311.
3. McCabe, N.R., Burnett, R.C., Gill, H.J., **Thirman, M.J.**, Mbangkollo, D., Kipiniak, M., van Melle, E., Ziemins-van der Poel, S., Rowley, J.D. and Diaz, M.O. Cloning of cDNAs of the MLL gene that detect DNA rearrangements and altered RNA transcripts in human leukemic cells with 11q23 translocations. *Proc. Natl. Acad. Sci. USA* 1992;89:1794-1798.
4. **Thirman, M.J.**, Gill, H.J., Burnett, R.C., Mbangkollo D., McCabe, N.R., Kobayashi, H., Ziemins-van der Poel, S., Kaneko, Y., Morgan, R., Sandberg, A.A., Chaganti, R.S.K., Larson, R.A., Le Beau, M.M., Diaz, M.O. and Rowley, J.D. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. *N. Engl. J. Med.* 1993;329:909-914.
5. Kobayashi, H., Espinosa III, R., **Thirman, M.J.**, Davis, E.M., Diaz, M.O., Le Beau, M.M. and Rowley J.D. Variability of 11q23 rearrangements in hematopoietic cell lines identified with fluorescence in situ hybridization. *Blood* 1993;81:3027-3033.
6. Kobayashi, H., Espinosa III, R., **Thirman, M.J.**, Gill, H., Fernald, A.A., Diaz, M.O., Le Beau, M.M. and Rowley, J.D. Heterogeneity of breakpoints of 11q23 rearrangements in hematologic malignancies identified with fluorescence in situ hybridization. *Blood* 1993;82:547-551.
7. Jani Sait, S.N., Raimondi, S.C., Look, A.T., Gill, H., **Thirman, M.J.**, Diaz, M.O. and Shows, T.B. A t(11;12) 11q23 leukemic breakpoint that disrupts the MLL gene. *Genes, Chrom., and Cancer* 1993;7:28-31.
8. Kobayashi, H., Espinosa III, R., **Thirman, M.J.**, Fernald, A.A., Shannon, K., Diaz, M.O., Le Beau, M.M. and Rowley, J.D. Do terminal deletions of 11q23 exist? Identification of undetected translocations with fluorescence in situ hybridization. *Genes, Chrom., and Cancer* 1993;7:204-208.
9. Gill, H.J., McCabe, N.R., **Thirman, M.J.**, Larson, R.A., Le Beau, M.M., Pedersen-Bjergaard, J., Preben, P., Diaz, M.O., and Rowley, J.D. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. *Blood* 1993;82:3705-3711.
10. Diaz, M.O., McCabe, N.R., Gill, H.J., **Thirman, M.J.**, Mbangkollo, D., Burnett, R.C., Ziemins-van der Poel, Le Beau, M.M., and Rowley, J.D. Analysis of 11q23 chromosome translocation breakpoints associated with human leukemia. *Cancer Chemotherapy* 1993;8:95-103.
11. McCabe, N.R., Kipiniak, M., Kobayashi, H., **Thirman, M.J.**, Gill, H., Rowley, J.D., and Diaz, M.O. DNA rearrangements and altered transcripts of the MLL gene in a human T-ALL cell line Karpas 45 with a t(X;11)(q13;q23) translocation. *Genes, Chrom., and Cancer* 1994;9:221-224.
12. **Thirman, M.J.**, Albrecht, J.H., Krueger, M.A., Erickson, R.R., Cherwitz, D.L., Park, S.S., Gelboin, H.V. and Holtzman, J.L. Induction of cytochrome CYP1A1 and formation of toxic metabolites of benzo[a]pyrene by rat aorta: a possible role in atherogenesis. *Proc. Natl. Acad. Sci. USA* 1994;91:5397-5401.
13. Burnett, R.C., **Thirman, M.J.**, Rowley, J.D. and Diaz, M.O. Molecular analysis of the T-Cell acute

lymphoblastic leukemia-associated t(1;7)(p34;q34) that fuses LCK and TCRB. *Blood* 1994;84:1232-1236.

14. Stock W., **Thirman, M.J.**, Dodge, R.K., Rowley, J.D., Diaz, M.O., Wurster-Hill, D., Sobol, R.E., Davey, F.R., Larson, R.A., Westbrook, C.A., and Bloomfield, C.D. Detection of MLL gene rearrangements in Adult Acute Lymphoblastic Leukemia. A Cancer and Leukemia Group B Study. *Leukemia* 1994;8:1918-1922.
15. **Thirman, M.J.**, Levitan, D.A., Kobayashi, H., Simon, M.C., and Rowley, J.D. Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia. *Proc. Natl. Acad. Sci. USA* 1994;91:12110-12114.
16. Martinez-Climent, J.A., **Thirman, M.J.**, Espinosa III, R., Le Beau, M.M. and Rowley, J.D. Detection of 11q23/MLL rearrangements in infant leukemias with fluorescence in situ hybridization and molecular analysis. *Leukemia* 1995;9:1299-1304.
17. Kobayashi, H., **Thirman, M.J.**, and Rowley, J.D. The U937 cell line has a t(10;11)(p13-14;q14-21) rather than a deletion of 11q. *Genes Chrom., & Cancer* 1995;13:217-218.
18. Mbangkollo, D., Burnett, R., McCabe, N., **Thirman, M.J.**, Gill, H., Yu, H., Rowley, J.D., and Diaz, M.O. The human MLL gene: Nucleotide sequence, homology to the Drosophila trx zinc-finger domain, and alternative splicing. *DNA and Cell Biology* 1995;14:475-483.
19. Martinez-Clement, J.A., Espinosa III, R, **Thirman, M.J.**, Le Beau, M.M., and Rowley, J.D. Abnormalities of chromosome band 11q23 and the MLL gene in pediatric myelomonocytic and monocytic leukemias: identification of the t(9;11) as an indicator of long survival. *Amer. J. Ped. Hematology/Oncology*, 1995;17:277-83.
20. Strissel-Broeker, P.L., Gill-Super, H.J., **Thirman, M.J.**, Pomykala, H., Yonebayashi Y., Tanabe, S., Zeleznik-Le, N.J., and Rowley, J.D. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: Correlation with scaffold attachment regions and topoisomerase II consensus binding sites. *Blood*, 1996;87:1912-1922.
21. Tanabe, S., Zeleznik-Le, N.J., Kobayashi, H., Espinosa R., Vignon, C., LeBeau, M.M., **Thirman, M.J.** and Rowley, J.D. Analysis of the t(6;11)(q27;q23) in leukemia shows a consistent breakpoint in AF6 in three patients and in the ML-2 cell line. *Genes, Chrom., and Cancer*, 1996;15:206-216.
22. **Thirman, M.J.**, Diskin, E.B., Bin, S.S., Ip, H.S., Miller, J.M., and Simon, M.C. Developmental analysis and subcellular localization of the murine homologue of ELL. *Proc. Natl. Acad. Sci. USA*, 1997;94:1408-1413.
23. Lavau C., Luo R.T., Du C., and **Thirman, M.J.** Retrovirus mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice. *Proc. Natl. Acad. Sci. USA*, 2000;97:10984-10989.
24. Lavau, C., Du, C., **Thirman, M.J.**, and Zeleznik-Le, N. Chromatin related properties of CBP fused to MLL generate an MDS-like syndrome that evolves into myeloid leukemia. *EMBO J.*, 2000;19:4655-4664.
25. Simone, F. Polak, P.E., Luo, R.T., Kaberlein, J.J., Levitan, D.A., and **Thirman, M.J.** EAF1, a novel ELL associated factor that is delocalized by expression of the MLL-ELL fusion protein. *Blood*, 2001;98:201-209.
26. Luo, R.T., Lavau, C., Du, C., Simone, F., Polak, P.E., Kawamata, S., and **Thirman, M.J.** The elongation domain of ELL is dispensable but its EAF1 interaction domain is essential for MLL-ELL

induced leukemogenesis. *Mol. Cell. Biol.*, 2001;21:5678-87.

27. Baron, B.B., Anastasi, J., **Thirman, M.J.**, Furukawa, Y., Fears, S., Kim D.C., Simone, F., Birkenbach, M., Montag, A., Sadhu, A., Zeleznik-Le, N., and McKeithan, T.W. The human programmed cell death-2 (PDCD2) gene is a novel target of BCL6 repression: implications for a role of BCL6 in the downregulation of apoptosis. *Proc. Natl. Acad. Sci. USA*, 2002;99:2860-2865.
28. Simone, F., Luo, R.T., Polak, P.E., Kaberlein, J.J., and **Thirman, M.J.** ELL-Associated Factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties. *Blood*, 2003;101:2355-2362.
29. Polak, P.E., Simone, F., Kaberlein, J.J., Luo, R.T., and **Thirman, M.J.** ELL and EAF1 are Cajal body components that are disrupted in MLL-ELL leukemia. *Molecular Biology of the Cell* 2003;14:1517-1528.
30. van Besien, K., Smith, S., Anastasi, J., Larson, R., **Thirman, M.J.**, Odenike, T., and Stock, W. Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. *Blood*. 2004;103:4373-4374.
31. Baron, B.W., Anastasi, J., Montag, A., Huo, D., Baron, R.M., Karrison, T., **Thirman, M.J.**, Subudhi, S.K., Chin, R.K., Felsher, D.W., Fu, Y.X., McKeithan, T.W., and Baron J.M. The human BCL6 transgene promotes the development of lymphomas in the mouse. *Proc. Natl. Acad. Sci. USA*. 2004;101:14198-14203.
32. Pascual, L.E., Tallec, L., Simone, F., Viengchareun, S., Meduri, G., **Thirman, M.J.**, and Lombes, M. The elongation factor ELL is a selective coregulator for steroid receptor functions. *Mol. Endocrinol.* 2005;19:1158-69.
33. van Besien, K., Artz, A., Smith, S., Cao, D., Rich, S., Godley, L., Jones, D., Del Cerro, P., Bennett, D., Casey, B., Odenike, O., **Thirman, M.J.**, Daugherty, C., Wickrema, A., Zimmerman, T., Larson, R.A., Stock, W. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. *J. Clin. Oncol.* 2005;23:5728-38.
34. Alexander, J.J., Aneziokoro, O.G., Chang, A., Hack, B.K., Markaryan, A., Jacob, A., Luo, R., **Thirman, M.J.**, Haas, M., and Quigg, R.J. Distinct and separable roles of the complement system in factor H-deficient bone marrow chimeric mice with immune complex disease. *J. Am. Soc. Nephrol.* 2006;17:1354-61.
35. Hahn, J., Xiao, W., Jiang, F., Simone, F., **Thirman, M.J.**, Wang Z. Apoptosis induction and growth suppression by U19/Eaf2 is mediated through its ELL-binding domain. *Prostate*;2007;67:146-153.
36. Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O, Zimmerman T, Smith S, Godley L, **Thirman M.J.**, Daugherty C, Extermann M, Larson R, van Besien K. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. *Biol Blood Marrow Transplant.*;2006 12:954-64.
37. Markus, J., Garin, M.T., Bies, J., Galili, N., Raza A., **Thirman, M.J.**, Le Beau, M.M., Rowley, J.D., Liu, P.P., Wolff, L. Methylation-independent silencing of the tumor suppressor INK4b(p15) by CBFbeta-SMMHC in acute myeloid leukemia. *Cancer Res.* 2007;67:992-1000.
38. Baron, B.W., Zeleznik-Le, N., Baron, M.J., Theisler, C., Huo, D., Krasowski, M.D., **Thirman, M.J.**, Baron, R.M., and Baron, J.M. Repression of the PDCD2 gene by BCL6 and the implications for the pathogenesis of human B and T cell lymphomas. *Proc. Natl. Acad. Sci. U S A.* 2007;104:7449-54.
39. Gordon, M.K., Sher, D., Karrison, T., Kebriaei, P., Chuang, K., Zhang, Y., McDonnell, D., Artz, A., Godley, L., Odenike, O., Rich, E., Michaelis, L., **Thirman, M.J.**, Wickrema, A., van Besien, K., Larson,

- R.A., and Stock, W. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. *Leuk Lymphoma*. 2008;49:531-7.
40. Chen, J., Santillan, D.L., Koonce, M., Wei, W., Luo, R., **Thirman, M.J.**, Zeleznik-Le, N.J., Diaz, M.O. Loss of MLL PHD-finger-3 is necessary for MLL-ENL-induced hematopoietic stem cell immortalization. *Cancer Research* 2008;68:6199-6207.
 41. Li, Z., Lu, J., Sun, M., Mi, S., Zhang, H., Luo, R.T., Chen, P., Wang, Y., Yan, M., Qian, Z., Neilly, M.B., Jin, J., Zhang, Y., Bohlander, S.K., Zhang, D.E., Larson, R.A., Le Beau, M.M., **Thirman, M.J.**, Golub, T.R., Rowley, J.D., Chen, J. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. *Proc. Natl. Acad. Sci. U S A.*, 2008;105:15535-40.
 42. Li, Z., Luo, R.T., Sun, M., Mi, S., Chen, P., Bao, J., Neilly, M.B., Jayathilaka, N., Johnson, D.S., Wang, L., Lavau, C., Zhang, Y., Tseng, C., Zhang, X., Wang, J., Yu, J., Yang, H., Wang, S.M., Rowley, J.D., Chen, J., **Thirman, M.J.** Consistent deregulation of gene expression between human and murine MLL-rearrangement leukemias *Cancer Research*, 2009;69:1109-16.
 43. Byun, J.S., Wong, M.M., Cui, W., Idelman, G., Li, Q., De Siervi, A., Bilke, S., Haggerty, C.M., Player, A., Wang, Y.H., **Thirman, M.J.**, Kaberlein, J.J., Petrovas, C., Koup, R.A., Longo, D., Ozato, K., Gardner, K. Dynamic bookmarking of primary response genes by p300 and RNA polymerase II complexes. *Proc Natl Acad Sci U S A*. 2009;106:19286-91.
 44. Mi, S., Li, Z., Chen, P., He, C., Cao, D., Elkahloun, A., Lu, J., Pelloso, L.A., Wunderlich, M., Huang, H., Luo, R.T., Sun, M., He, M., Neilly, M.B., Zeleznik-Le, N.J., **Thirman, M.J.**, Mulloy, J.C., Liu, P.P., Rowley, J.D., Chen, J. Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. *Proc Natl Acad Sci U S A*. 2010;107:3710-5.
 45. Baron, B.W., Hyjek, E., Gladstone, B., **Thirman, M.J.**, Baron, J.M. PDCD2, a protein whose expression is repressed by BCL6, induces apoptosis in human cells by activation of the caspase cascade. *Blood Cells Mol Dis*. 2010;45:169-75.
 46. Odenike, O., **Thirman, M.J.**, Artz, A.S., Godley, L.A., Larson, R.A., Stock, W. Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? *Semin Oncol*. 2011;38:196-214.
 47. Wang, Q.F., Wu, G., Mi, S., He, F., Wu, J., Dong, J., Luo, R.T., Mattison, R., Kaberlein, J., Prabhakar, S., Ji, H., **Thirman, M.J.** MLL fusion proteins preferentially regulate a subset of wild type MLL target genes in the leukemic genome. *Blood* 2011;117:6895-905.
 48. Artz, A.S., **Thirman, M.J.** Unexplained anemia predominates despite an intensive evaluation in a racially diverse cohort of older adults from a referral anemia clinic. *J Gerontol A Biol Sci Med Sci*. 2011;66:925-32.
 49. Larson, S.M., Campbell, N.P., Huo, D., Artz, A., Zhang, Y., Gajria, D., Green, M., Weiner, H., Daugherty, C., Odenike, O., Godley, L.A., Hyjek, E., Gurbuxani, S., **Thirman, M.J.**, Sipkins, D., Van Besien, K., Larson, R.A., Stock, W. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). *Leuk Lymphoma*. 2012;53:445-50.
 50. Baron, B.W., Anastasi, J., Hyjek, E.M., Bies, J., Reddy, P.L., Dong, J., Joseph, L., **Thirman, M.J.**, Wroblewski, K., Wolff, L., Baron, J.M. PIM1 gene cooperates with human BCL6 gene to promote the development of lymphomas. *Proc Natl Acad Sci U S A*. 2012;109:5735-9.
 51. Grdina, D.J., Murley, J.S., Miller, R.C., Mauceri, H.J., Sutton, H.G., **Thirman, M.J.**, Li, J.J., Woloschak, G.E., Weichselbaum, R.R. A Manganese Superoxide Dismutase (SOD2)-Mediated Adaptive Response. *Radiat Res*. 2013;179:115-24.

52. Locke, F., Agarwal, R., Kunnavakkam, R., van Besien, K., Larson, R.A., Odenike, O., Godley, L.A., Liu, H., Le Beau, M.M., Gurbuxani, S., **Thirman, M.J.**, Sipkins, D., White, C., Artz, A., Stock, W. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. *Bone Marrow Transplant.* 2013;48:1437-43.
53. Baron, B.W., Anastasi, J., Bies, J., Reddy, P.L., Joseph, L., **Thirman, M.J.**, Wroblewski, K., Wolff, L., Baron, J.M. GFI1B, EVI5, MYB-Additional genes that cooperate with the human BCL6 gene to promote the development of lymphomas. *Blood Cells Mol Dis.* 2014;52:68-75.
54. Wang, Q.F., Li, Y.J., Dong, J.F., Li, B., Kaberlein, J.J., Zhang, L., Arimura, F.E., Luo, R.T., Ni, J., He, F., Wu, J., Mattison, R., Zhou, J., Wang, C.Z., Prabhakar, S., Nobrega, M.A., **Thirman, M.J.** Regulation of MEIS1 by distal enhancer elements in acute leukemia. *Leukemia.* 2014;28:138-46. PMID: 21518926
55. O'Brien S., Jones, J.A., Coutre, S.E., Mato, A.R., Hillmen, P., Tam, C., Osterborg, A., Siddiqi, T., **Thirman, M.J.**, Furman, R.R., Ilhan, O., Keating, M.J., Call, T.G., Brown, J.R., Stevens-Brogan, M., Li, Y., Clow, F., James, D.F., Chu, A.D., Hallek, M., and Stilgenbauer, S. Ibrutinib Therapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: the Phase 2, Open-label, Multicenter RESONATE-17 Study. *Lancet Oncol.* 2016;17:1409-1418. PMID: 27637985
56. Lin, S., Luo, R.T., Ptasińska, A., Kerry, J., Assi, S.A., Wunderlich, M., Imamura, T., Kaberlein, J.J., Rayes, A., Althoff, M.J., Anastasi, J., O'Brien, M.M., Meetei, A.R., Milne, T.A., Bonifer, C.C., Mulloy, J.C., **Thirman, M.J.** Instructive role of MLL fusion proteins revealed by a model of t(4;11) pro-B acute lymphoblastic leukemia. *Cancer Cell.* 2016;30:737-749. PMID: 27846391
57. Khan N., Hantel A., Knoebel R.W., Artz A., Larson R.A., Godley L.A., **Thirman M.J.**, Liu H., Churpek J.E., King D., Odenike O., Stock W. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. *Leuk Lymphoma.* 2017;58:1-7. PMID: 28278716
58. Lin S., Luo R.T., Shrestha M., **Thirman M.J.**, Mulloy J.C. The full transforming capacity of MLL-Af4 is interlinked with lymphoid lineage commitment. *Blood.* 2017;130:903-907. PMID: 28637661
59. **Thirman M.J.** Paradoxical Effects of MLL Paralogs in MLL-Rearranged Leukemia. *Cancer Cell.* 2017;31:729-731. PMID: 28609652
60. Kadri S., Lee J., Fitzpatrick C., Galanina N., Sukhanova M., Venkataraman G., Sharma S., Long B., Petras K., Theissen M., Ming M., Kobzev Y., Kang W., Guo A., Wang W., Niu N., Weiner H., **Thirman M.**, Stock W, Smith SM, Nabhan C, Segal JP, Lu P, Wang YL. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. *Blood Adv.* 2017;1:715-727.
61. Wang A.Y., Weiner H., Green M., Chang H., Fulton N., Larson R.A., Odenike O., Artz A.S., Bishop M.R., Godley L.A., **Thirman M.J.**, Kosuri S, Churpek JE, Curran E, Pettit K, Stock W, Liu H. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. *J Hematol Oncol.* 2018;11:4.
62. DiNardo C.D., Pratz K.W., Letai A., Jonas B.A., Wei A.H., **Thirman M.**, Arellano M., Frattini M.G., Kantarjian H., Popovic R., Chyla B., Xu T., Dunbar M., Agarwal S.K., Humerickhouse R., Mabry M., Potluri J., Konopleva M., Pollyea D.A. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. *Lancet Oncol.* 2018;19:216-228.
63. Baron B.W., **Thirman M.J.**, Giurcanu M.C., Baron J.M. Quercetin Therapy for Selected Patients with PIM1 Kinase-Positive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pilot Study. *Acta Haematol.* 2018;139:132-139.

64. Byrd, J.C., Ruppert, A.S., Heerema, N.A., Halvorson, A.E., Boyd, M., Hoke, E., Smith, M.R., Godwin, J.E., Couban, S., Fehniger, T.A., **Thirman, M.**, Tallman, M.S., Appelbaum, F.R., Stone, R.M., Robinson, S., Chang, J.E., Mandrekar, S.J., Larson, R.A. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). *Blood Adv.* 2018;2:1705-1718.
65. Osman, A.E.G., Anderson, .J, Churpek, J.E., Christ, T.N., Curran, E., Godley, L.A., Liu, H., **Thirman, M.J.**, Odenike, T., Stock, W., Larson, R.A. Treatment of Acute Promyelocytic Leukemia in Adults. *J Oncol Pract.* 2018;14:649-657.
66. Awan F.T., **Thirman M.J.**, Patel-Donnelly D., Assouline S., Rao A.V., Ye W., Hill B., Sharman J.P. Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study. *Leuk Lymphoma.* 2019;11:1-6.
67. Jeong J.J., Gu X., Nie J., Sundaravel S., Liu H., Kuo W.L., Bhagat T.D., Pradhan K., Cao J., Nischal S., McGraw K.L., Bhattacharyya S., Bishop M.R., Artz A., **Thirman M.J.**, Moliterno A., Ji P, Levine R.L., Godley L.A., Steidl U., Bieker J.J., List A.F., Sauntharajah Y., He C., Verma A., Wickrema A. Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. *Cancer Discovery* 2019;9:778-795.
68. Cahill K.E., Karimi Y.H., Karrison T.G., Jain N., Green M., Weiner H., Fulton N., Kadri S., Godley L.A., Artz A.S., Liu H., **Thirman M.J.**, Le Beau M.M., McNeerney M.E., Segal J., Larson R.A., Stock W., Odenike O. A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. *Blood Adv.* 2020;4:599-606.
69. Patel, A.A., Cahill, K., Charnot-Katsikas, A., Liu, H., Gurbuxani, S., **Thirman, M.**, Kosuri, S., Artz, A.S., Larson, R.A., Stock, W., Segal, J., and Odenike, O. Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. *Br. J Haematol.* 2020;190:e48-e51.
70. DiNardo, C.D., Jonas, B.A., Pullarkat, V., **Thirman, M.J.**, Garcia, J.S., Wei, A.H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., Koller, E., Havelange, V., Leber, B., Esteve, J., Wang, J., Pejsa, V., Hájek, R., Porkka, K., Illés, Á., Lavie, D., Lemoli, R.M., Yamamoto, K., Yoon, S.S., Jang, J.H., Yeh, S.P., Turgut, M., Hong, W.J., Zhou, Y., Potluri, J., and Pratz, K.W. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. *N. Engl. J. Med.* 2020;383:617-629.
71. Patel A.A., Heng J., Dworkin E., Monick S., Derman B., DuVall A., Gurbuxani S., Kosuri S., Liu H., **Thirman M.**, Godley L., Odenike O., Larson R., Stock W. Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. *EJHaem.* 2021; 3:413-420.
72. Pollyea, D.A., Pratz, K., Letai, A., Jonas, B.A., Wei, A.H., Pullarkat, V., Konopleva, M., **Thirman, M.J.**, Arellano, M., Becker, P.S., Chyla, B., Hong, W.J., Jiang, Q., Potluri, J., and DiNardo, C.D. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. *Am J Hematol.* 2021;96:208-217.
73. Pratz, K.W., Jonas, B.A., Pullarkat, V., Recher, C., Schuh, A.C., **Thirman, M.J.**, Garcia, J.S., DiNardo, C.D., Vorobyev, V., Fracchiolla, N.S., Yeh, S., Jang, J.J., Ozcan, M., Yamamoto, K., Illes, A., Zhou, Y., Dail, M., Chyla, B., Potluri, J., Döhner, H. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia with Venetoclax and Azacitidine. *J. Clin. Oncol.* 2022;40:855-865.
74. Konopleva, M.K., **Thirman, M.J.**, Pratz, K.W., Garcia, J.S., Recher, C., Pullarkat, V., Kantarjian, H.M., DiNardo, C.D., Dail, M., Duan, Y., Chyla, B., Potluri, J., Miller, C.L., Wei, A.H. Impact of FLT3 mutation

on outcomes after venetoclax and azacitidine for patients with treatment-naïve acute myeloid leukemia. *Clin Cancer Res.* 2022; 28:2744-2752.

75. Tirtakusuma, R., Szoltysek, K., Milne, P., Grinev, V.V., Ptasinska, A., Chin, P.S., Meyer, C., Nakjang, S., Hehir-Kwa, J.Y., Williamson, D., Cauchy, P., Keane, P., Assi, S.A., Ashtiani, M., Kellaway, S.G., Imperato, M.R., Vogiatzi, F., Schweighart, E.K., Lin, S., Wunderlich, M., Stutterheim, J., Komkov, A., Zerkalenskova, E., Evans, P., McNeill, H., Elder, A., Martinez-Soria, N., Fordham, S.E., Shi, Y., Russell, L.J., Pal, D., Smith, A., Kingsbury, Z., Becq, J., Eckert, C., Haas, O.A., Carey, P., Bailey, S., Skinner, R., Miakova, N., Collin, M., Bigley, V., Haniffa, M., Marschalek, R., Harrison, C.J., Cargo, C.A., Schewe, D., Olshanskaya, Y., **Thirman, M.J.**, Cockerill, P.N., Mulloy, J.C., Blair, H.J., Vormoor, J., Allan, J.M., Bonifer, C., Heidenreich, O., Bomken, S. Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia. *Blood.* 2022;140:1875-1890. doi: 10.1182/blood.2021015036.
76. Roloff, G.W., Wen, F., Ramsland, A., Artz, A.S., Kosuri, S., Stock, W., Odenike, O., Larson, R.A., Liu, H., Godley, L.A., **Thirman, M.J.**, Patel, A.A., Daugherty, C.K., DuVall, A.S., Nawas, M.T., Dworkin, E., Wool, G.D., Gurbuxani, S., Fitzpatrick, C., Segal, J.P., Wang, P., Drazer, M.W. Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. *Haematologica.* 2023;108(8):2234-2239. doi: 10.3324/haematol.2022.282148.
77. Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, **Thirman M.J.**, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, Stein EM. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. *Nature.* 2023;615(7954):920-924. doi: 10.1038/s41586-023-05812-3.
78. Johnston, H., Youshanlouei, H.R., Osei, C., Patel, A.A., DuVall, A., Wang, P., Wanjari, P., Segal, J., Venkataraman, G., Cheng, J.X., Gurbuxani, S., Lager, A., Fitzpatrick, C., **Thirman, M.**, Nawas, M., Liu, H., Drazer, M., Odenike, O., Larson, R., Stock, W., Saygin, C. Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. *Blood Adv.* 2024;8(1):164-171. doi: 10.1182/bloodadvances.2023011862.
79. Madero-Marroquin R., Dworkin, E., Weiner, H., Saygin, C., Nawas, M.T., Drazer, M.W., DuVall, A.S., Kosuri, S., **Thirman, M.J.**, Odenike, O., Stock, W., Larson, R.A., Patel, A.A. Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. *Leuk Lymphoma.* 2024;1-4. doi: 10.1080/10428194.2024.2324991.
80. Pratz, K.W., Jonas, B.A., Pullarkat, V., **Thirman, M.J.**, Garcia, J.S., Döhner, H., Récher, C., Fiedler, W., Yamamoto, K., Wang, J., Yoon, S.S., Wolach, O., Yeh, S.P., Leber, B., Esteve, J., Mayer, J., Porkka, K., Illés, Á., Lemoli, R.M., Turgut, M., Ku, G., Miller, C., Zhou, Y., Zhang, M., Chyla, B., Potluri, J., DiNardo, C.D. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. *Am J Hematol.* 2024;99(4):615-624. doi: 10.1002/ajh.27246.
81. Issa, G.C., Aldoss, I., **Thirman, M.J.**, DiPersio, J., Arellano, M., Blachly, J.S., Mannis, G.N., Perl, A., Dickens, D.S., McMahon, C.M., Traer, E., Zwaan, C.M., Grove, C.S., Stone, R., Shami, P.J., Mantzaris, I., Greenwood, M., Shukla, N., Cuglievan, B., Kovacsics, T., Gu, Y., Bagley, R.G., Madigan, K., Chudnovsky, Y., Nguyen, H.V., McNeer, N., Stein, E.M. Menin Inhibition with Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). *J Clin Oncol.* 2025;43(1):75-84. doi: 10.1200/JCO.24.00826. PMID: 39121437
82. Döhner H., Pratz, K.W., DiNardo, C.D., Wei, A.H., Jonas, B.A., Pullarkat, V., **Thirman, M.J.**, Récher, C., Schuh, A.C., Babu, S., Li, X., Ku, G., Liu, Z., Sun, Y., Potluri, J., Dail, M., Chyla, B., Pollyea, D.A. Genetic Risk Stratification and Outcomes Among Treatment-Naïve Patients With AML Treated With Venetoclax and Azacitidine. *Blood.* 2024 Aug 12;blood.2024024944. doi:0.1182/blood.2024024944. Online ahead of print. PMID: 39133921

83. Pullarkat V, Pratz KW, Döhner H, Recher C, **Thirman M.J.**, DiNardo CD, Fenaux P, Schuh AC, Wei AH, Pigneux A, Jang JH, Juliusson G, Miyazaki Y, Selleslag D, Arellano ML, Liu C, Ridgeway JA, Potluri J, Schuler J, Konopleva M. Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia. *Blood Cancer J.* 2025;15(1):49. doi: 10.1038/s41408-025-01263-3. PMID: 40155601; PMCID: PMC11953227.
84. Arellano, M.L., **Thirman, M.J.**, DiPersio, J.F., Heiblig, M., Stein, E.M., Schuh, A.C., Žučenka, A., de Botton, S., Grove, C.S., Mannis, G.N., Papayannidis, C., Perl, A.E., Issa, G.C., Aldoss, I., Bajel, A., Dickens, D.S., Kühn, M.W.M., Mantzaris, I., Raffoux, E., Traer, E., Amitai, I., Döhner, H., Greco, C., Kovacsovics, T., McMahon, C.M., Montesinos, P., Pigneux, A., Shami, P.J., Stone, R.M., Wolach, O., Harpel, J.G., Chudnovsky, Y., Yu, L., Bagley, R.G., Smith, A.R. and Blachly, J.S. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. *Blood* 2025;146(9):1065-1077. doi: 10.1182/blood.2025028357. PMID: 40332046.
85. Venditti, A., Hou J.Z., Fenaux, P., Jonas, B.A., Vrhovac, R., Montesinos, P., Garcia, J.S., Rizzieri, D., **Thirman, M.J.**, Zhang, M., Potluri, J., Miller, C., Dhalla, M., Pullarkat, V. Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model. *Leukemia.* 2025 Nov;39(11):2697-2707. doi: 10.1038/s41375-025-02730-3. Epub 2025 Sep 5. PMID: 40913104; PMCID: PMC12589120.
86. Madero-Marroquin, R., Cannova, J., Dworkin, E., Wesevich, A., Roloff, G.W., Saygin, C., Nawas, M.T., DuVall, A.S., Kosuri, S., **Thirman, M.J.**, Odenike, O., Stock, W., Larson, R.A., Drazer, M.W., Patel, A.A. Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy. *EJHaem.* 2025 Jun 13;6(3):e70078. doi: 10.1002/jha2.70078. PMID: 40521395; PMCID: PMC12163342.
87. Thomas, M., Johnston, H., Dworkin, E., Wesevich, A., Roloff, G.W., Saygin, C., Nawas, M.T., Drazer M.W., DuVall, A.S., Kosuri, S., **Thirman, M.J.**, Odenike, O., Stock, W., Larson, R.A., Madero-Marroquin, R., Patel, A.A. Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies. *Br J Haematol.* 2026 Jan;208(1):343-347. doi: 10.1111/bjh.70225. Epub 2025 Oct 26. PMID: 41139955; PMCID: PMC12819088.
88. Pratz, K.W., DiNardo, C.D., Arellano, M., **Thirman, M.J.**, Pullarkat, V., Becker, P.S., Smith, B.D., Zhang, M., Miu, K., Potluri, J., Pollyea, D.A. Long-Term Outcomes of Stem Cell Transplant in Older Patients With Acute Myeloid Leukemia Treated With Venetoclax-Based Therapies. *Am J Hematol.* 2026 Jan 9. doi: 10.1002/ajh.70204. Epub ahead of print. PMID: 41510611.
89. Cannova, J.M., Battaglia, M.R., Roloff, G.W., Cetin, S., Tallarico, M., Stock, W., Patel, A.A., Odenike, O., Larson, R.A., **Thirman, M.J.**, Nawas, M.T., Wang, P., Tjota, M.Y., Segal, J.P., Venkataraman G, DuVall AS, Drazer MW. Hematologic complications in patients exposed to poly-ADP ribose polymerase inhibitors. *Haematologica.* 2026 Jan 29. doi: 10.3324/haematol.2025.288518. Epub ahead of print. PMID: 41609051.

Book Chapters:

1. **Thirman, M.J.**, and Larson, R.A. Therapy-related myeloid leukemia. Hematology/Oncology Clinics of North America, 1996;10:293-320.
2. Stock, W. and **Thirman, M.J.** Pathobiology of acute myeloid leukemia. In: Hematology Basic Principles and Practice. Hoffman et al. (eds) Churchill and Livingstone, 1999;979-999.
3. Stock, W. and **Thirman, M.J.** Molecular biology of acute promyelocytic leukemia. In: UpToDate 2002-2024 (Online).
4. Stock, W. and **Thirman, M.J.** Pathogenesis of acute myeloid leukemia. In: UpToDate 2002-2024 (Online).
5. Stock, W. and **Thirman, M.J.** Molecular genetics of acute myeloid leukemia. In: UpToDate 2002-2024 (Online).

INVITED SPEAKING

1998 Functional Characterization of the MLL-ELL Fusion Protein in Acute Myeloid Leukemia. Loyola University Medical Center, Maywood, IL

1999 Functional Characterization of the MLL-ELL Fusion Protein in Acute Myeloid Leukemia. University of Colorado, Denver, CO

2001 Molecular Dissection of MLL-ELL Leukemogenesis. AACR Symposium on Chromosome Translocations in Hematopoietic Malignancies, New Orleans, LA

2001 EAF1, a Novel ELL Associated Factor, is Delocalized by Expression of the MLL-ELL Fusion Protein and is Essential for MLL-ELL Induced Leukemogenesis. Fourth International Meeting on Molecular Aspects of Myeloid Stem Cell Development, Annapolis, MD

2001 Molecular analysis of the MLL-ELL fusion protein in the development of acute leukemia. University of Illinois at Chicago, Chicago, IL

2002 Molecular Analysis of the MLL-ELL Fusion Protein in Acute Myeloid Leukemia. Memorial Sloan-Kettering Cancer Center Grand Rounds, New York, NY

2002 Molecular Analysis of the MLL-ELL Fusion Protein in Acute Myeloid Leukemia. University of Michigan, Ann Arbor, MI

2003 Cooperating Mutations Are Necessary for the Development of AML In MLL-ELL Knock-In Mice. Fifth International Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia, Annapolis, MD

2004 The role of ELL and EAF family members in leukemogenesis, Northwestern University, Chicago, IL

2004 MLL and ELL in Leukemogenesis, Loyola University Medical Center, Maywood, IL

2005 MLL-ELL associated leukemogenesis, University of Illinois at Chicago, Chicago, IL

2005 The interaction of ELL and EAF1 provides a therapeutic target in MLL-ELL leukemia, Sixth International Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia, Annapolis, MD

2005 American Society of Hematology meeting, Meet the Expert session, MLL-Associated Leukemia, Atlanta, GA

2006 Targeted therapy in leukemia. Karmanos Cancer Institute/Wayne State University School of Medicine, Detroit, MI

2007 Complex molecular interactions required for the immortalization activity of MLL-Gephyrin, Seventh International Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia, Annapolis, MD

2007 Targeting MLL fusion genes in leukemia. Scientific Committee on Myeloid Neoplasia, American Society of Hematology meeting, Atlanta, GA

2009 Cooperating genes in MLL rearranged leukemia. Eighth International Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia, Annapolis, MD.

2009 The MLL-ELL Fusion Protein in Leukemogenesis. Stowers Institute for Medical Research, Kansas City, MO

2011 Molecular Targets in MLL-Rearranged Leukemia. University of Pennsylvania, Philadelphia, PA

2011 Molecular Pathogenesis of MLL-Rearranged Acute Leukemia. Northwestern University, Chicago, IL

2012 Peptide Therapeutics for MLL rearranged leukemia. Leukemia and Lymphoma Society SCOR meeting, New York, NY

2013 Modeling exposure-induced leukemogenesis in the mouse. The Bone Marrow Niche, Stem Cells, & Leukemia: Impact of Drugs, Chemicals, and Environment. New York Academy of Sciences, New York, NY

2014 Pathogenesis and Treatment of MLL Rearranged Leukemia. University of Arkansas Medical School, Little Rock, AR

2015 Society of Hematologic Oncology 2015 Annual Meeting. Targeting MLL Leukemias: New Therapeutic Strategies, Houston, TX

2015 American Society of Hematology Workshop on Myeloid Development. A Novel MLL-AF4 In Vivo Model Phenocopies t(4;11) Pro-B ALL and Reveals a Lymphoid Lineage Bias of the Fusion Protein in Human Cells, Orlando, FL

2016 11th International Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia.
Transducible MLL peptide exhibits significant activity in combination with DOT1L and CDK9 inhibitors. Cincinnati, OH

2016 The Geoffrey P. Herzig, M.D. Memorial Symposium for Hematologic Malignancies and Bone Marrow Transplantation. Leukemogenesis Mediated by MLL Fusion Proteins. Louisville, KY

2016 Developing a Faithful Mouse Model to Address the Conundrum of MLL-AF4 Leukemogenesis. Loyola University Medical Center, Maywood, IL

2017 Developing a Faithful Mouse Model to Address the Conundrum of MLL-AF4 Leukemogenesis. Northwestern University, Chicago, IL

2018 Modeling and Analysis of MLL-Rearranged Leukemia. Blood Research Institute Blood Center of Wisconsin, Milwaukee, WI

2018 Clonal Evolution and Richter Transformation in patients with ibrutinib-relapsed CLL. CLL Expert Forum, Dallas, TX

2019 Role of SYK Inhibition in CLL/Combining Umbralisib and Pembrolizumab in CLL. CLL Expert Forum, Dallas, TX

2020 Menin Inhibition for MLL-Rearranged and NPM1 Mutant Leukemias. Global Summit on Hematologic Malignancies, Whistler, British Columbia

2022 Current Data Targeting MLL/NPM-1 in Acute Leukemia. Global Summit on Hematologic Malignancies, Whistler, British Columbia

2023 Hematologic Malignancies Expert Panel, Precisca National Meeting, Miami, FL

2024 Biomarkers of Response to Revumenib in MLL-Rearranged Leukemia. Global Summit on Hematologic Malignancies, Whistler, British Columbia

2024 Hematologic Malignancies Expert Panel, Precisca National Meeting, Miami, FL

2024 Menin Inhibitor Therapies for MLL-Rearranged and NPM1 mutated Leukemias. Indy Hematology Rare Disease Symposium, Indianapolis, IN

2025 Hematologic Malignancies Expert Panel, Precisca National Meeting, Miami, FL

2025 Overcoming Resistance Mechanisms to Menin Inhibitors. Global Summit on Hematologic Malignancies, Whistler, British Columbia

INVITED, ELECTED, OR APPOINTED EXTRAMURAL SERVICE

Editorial Boards:

1. 2002-2007 *Cancer Biology and Therapy*
2. 2005-2009 *Leukemia and Lymphoma*
3. 2016-2021 *Blood Advances*

TEACHING

For Graduate programs (Ph.D.):

2003- Cancer Biology I course.
1) Molecular Aspects of Leukemogenesis
2) Mouse Models of Leukemia
These two lectures cover the molecular genetic studies that provide the current basis for examining the pathogenesis of acute leukemia and the experimental strategies that have been employed to dissect these mechanisms using mouse models.

For Pritzker School of Medicine (M.D.):

(a) Didactic

1996- CPP laboratory faculty once per year

(b) Clinical

1996- Daily rounding including ~2 medical students during 1-2 months per year on service

For Graduate medical education (residency and clinical fellowships):

(b) Clinical

1996- Daily rounding including ~2 residents and 1 fellow during 1-2 months per year on service

1996- Work with 1-2 residents and 1 fellow in twice weekly Hematology/Oncology Clinics

Research trainees:

1998-2000 Spero Cataland, M.D. Presently Professor, Ohio State University
2000-2003 Partow Kebriaei, M.D. Presently Professor, MD Anderson Cancer Center
1997-2003 Roger Luo, Ph.D. Presently Research Professional University of Chicago
1996-2003 Federico Simone, Ph.D. Presently patent attorney
2004-2007 Toshihiko Imamura, M.D., Ph.D. Presently Associate Professor, Kyoto Prefectural University of Medicine
2006-2010 Nimisha Sharma, Ph.D. Presently Associate Professor, University School of Biotechnology, G.G.S.Indraprastha University
2006-2011 Andre Hahn, Ph.D. Presently Student, University of North Carolina Business School
2007-2009 Ryan Mattison, M.D. Presently Associate Professor, University of Wisconsin
2021- Aysenur Esen, M.D. Presently Pediatric Hematology/Oncology Instructor, University of Chicago

SERVICE

Committee membership:

2001-2002 American Cancer Society, Illinois Division, Grant Review Committee
2001-2012 University of Chicago Cancer Center, American Cancer Society Institutional Research Grant Review Committee
2003, 2006 Leukemia and Lymphoma Society Translational Research Grant Review Committee
2008-2009 Member, Tumor Biology Committee, American Society of Clinical Oncology
2016-2021 University of Chicago Cancer Center Scientific and Accrual Monitoring Committee
2017-2020 University of Chicago Institutional Review Board
2015-2023 Leukemia and Lymphoma Society Illinois Chapter Board of Trustees
2002- Leukemia Research Foundation Medical Advisory Board/ Grant Review Committee
2020- University of Chicago Protocol Review and Monitoring Committee
2023- Alliance CLL Committee
2023- Alliance AML Committee

Leadership:

2005-2009 Chair, Leukemia Research Foundation Medical Advisory Board/ Grant Review Committee
2007-2014 Co-Program Leader, University of Chicago Cancer Research Center, Hematopoiesis and Hematologic Malignancies Program